85-4452-53 [取扱停止]Interleukin-13, active (IL13), Recombinant, Human 2ug 348104
特徴
- Cytokine. Inhibits inflammatory cytokine production. Synergizes with IL2 in regulating interferon-gamma synthesis. May be critical in regulating inflammatory and immune responses.
- Biological Activity:Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using human TF-1 cells is less than 0.5ng/ml, corresponding to a specific activity of > 2.0x10e6 IU/mg.
- Sequence:GPVPPSTALR ELIEELVNIT QNQKAPLCNG SMVWSINLTA GMYCAALESL INVSGCSAIE KTQRMLSGFC PHKVSAGQFS SLHVRDTKIE VAQFVKDLLL HLKKLFREGQ FN
- Molecular Weight:12.3kD
- PubMed ID:8096327; 8097324; 7721105; 8605348; 15372022; 15489334; 1408833; 11419948; 20223216; 10699178; 11588017; 12928861
- Gene Name:IL13,NC30
- Swiss Prot:P35225
- Storage and Stability:Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
仕様
- Size:2ug
- Source Antigen:Recombinant, Human, E. coli
- Grade:Highly Purified
- Purity:≥97% as determined by SDS-PAGE and HPLC.
- Form:Lyophilized from 0.2um filtered PBS, pH 7.2, with 5% Trehalose
- Molecular Weight Non Ab:12.3
- Swiss Prot Number:P35225
- EU Commodity Code:30021019
- この商品は法規制を確認しておりません。(法規制によって販売できない場合もございます)
- 製品の仕様は予告なく変更になる場合がございます。最新仕様はメーカーホームページをご確認ください。
- 【試薬に関するお問合せ】
- アズワン株式会社 試薬・プロセス材料グループ
- TEL:06-6447-8641
- FAX:06-6447-8642
- E-mail:[email protected]
商品のバリエーション (サイズ違い・スペック違い・オプション品など)
| 商品イメージ | アズワン品番 商品名 |
|---|---|
|
85-4452-54
Interleukin-13, active (IL13), Recombinant, Human 10ug
|
|
|
85-4452-55
Interleukin-13, active (IL13), Recombinant, Human 100ug
|
|
|
85-4452-53
Interleukin-13, active (IL13), Recombinant, Human 2ug
|
よくあるご質問(FAQ)
掲載カタログ情報
| 掲載カタログ名 | 掲載ページ |
|---|





